A detailed history of Rhumbline Advisers transactions in Morpho Sys Ag stock. As of the latest transaction made, Rhumbline Advisers holds 5,187 shares of MOR stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,187
Previous 5,187 -0.0%
Holding current value
$0
Previous $94,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 01, 2024

BUY
$17.36 - $19.34 $13,627 - $15,181
785 Added 17.83%
5,187 $94,000
Q1 2024

May 09, 2024

BUY
$8.6 - $18.18 $5,151 - $10,889
599 Added 15.75%
4,402 $79,000
Q4 2023

Feb 08, 2024

BUY
$4.55 - $9.9 $11,852 - $25,789
2,605 Added 217.45%
3,803 $37,000
Q3 2023

Nov 09, 2023

BUY
$6.72 - $8.6 $2,251 - $2,881
335 Added 38.82%
1,198 $8,000
Q2 2023

Aug 08, 2023

BUY
$3.95 - $7.74 $3,408 - $6,679
863 New
863 $6,000

Others Institutions Holding MOR

About MorphoSys AG


  • Ticker MOR
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 136,614,000
  • Description
  • MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, f...
More about MOR
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.